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SUMMARY
Objective: We report the treatment of a patient with persistent gestational trophoblastic disease.
Case Report: A 42-year-old woman, gravida 2, para 1, was initially diagnosed with choriocarcinoma from
curettage specimens. She initially responded to aggressive chemotherapy but later was unresponsive.
Subsequently, she underwent total abdominal hysterectomy; the resected uterus revealed a placental site
trophoblastic tumor. Adjuvant chemotherapy was given. The serum human chorionic gonadotropin level
progressively decreased to zero. The patient was alive and well at the time of writing.
Conclusion: Chemotherapy-resistant persistent gestational trophoblastic disease may suggest placental site
trophoblastic tumor. Surgery is the main treatment for placental site trophoblastic tumor. [Taiwanese J Obstet
Gynecol 2004;43(2):120–124]
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Introduction
Placental site trophoblastic tumor (PSTT) is the rarest
type of gestational trophoblastic disease derived from
intermediate trophoblasts. Since it was first reported
by Kurman et al in 1976 [1], more than 100 cases have
been reported in the English literature. As it is infre-
quently seen, the clinical behavior and pathogenesis
of PSTT are still not completely understood. Here, we
present a case of PSTT and review the literature for
management options.
Case Report
A 42-year-old woman, gravida 2, para 1, presented with
irregular genital bleeding for 3 months. She had under-
gone therapeutic dilatation and curettage (D&C) for
a spontaneous abortion in May 2002. Otherwise, the
patient was in excellent health. A D&C was performed
on May 2, 2003, at another hospital because of irregu-
lar genital bleeding. The pathology report interpreted
the specimen as a choriocarcinoma. The serum hu-
man chorionic gonadotropin (β-hCG) concentration
was elevated to 1,798 mIU/mL. She was treated with
EMA/CO chemotherapy (etoposide 100 mg/m2 on
days 1 and 2, methotrexate 100 mg/m2 on day 1 followed
immediately by a 12-hour infusion of 200 mg/m2
methotrexate with leukovorin rescue on days 2 and 3,
actinomycin-D 0.5 mg on days 1 and 2, and then vin-
cristine 1.0 mg/m2 and cyclophosphamide 600 mg/m2
on day 8). After two courses of chemotherapy, her
serum β-hCG dropped to 36.7 mIU/mL. However,
this increased to 94 mIU/mL at the end of the third
cycle of chemotherapy, so she was referred to our
institution. Our studies included brain, chest,
abdominal, and pelvic computed tomography that
revealed no evidence of metastatic lesions. Pelvic ul-
trasonography revealed a normal-sized uterus with
no significant masses.
One cycle of chemotherapy consisting of PE (cispla-
tin 50 mg/m2 on day 1, etoposide 100 mg/m2 on days 1
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and 2) was administered, and the β-hCG concentration
decreased from 214 to 190 mIU/mL. At this time, the
diagnosis was revised to PSTT because of the persistence
of a low level of β-hCG that was refractory to EMA/CO
treatment. The patient underwent total abdominal
hysterectomy on July 10, 2003. The cut surface of her
normal-sized uterus incidentally revealed a necrotic,
soft mass measuring 0.8 × 0.5 × 0.5 cm in the endocer-
vical wall (Figure 1). Grossly, the tumor had invaded
nearly one-third of the thickness of the cervical myo-
metrium. Microscopically, the tumor was composed of
typical polygonal cells, most of which were mononu-
cleate, but some of which were multinucleate (Figure
2). These findings were consistent with intermediate
trophoblastic cells that had infiltrated the myometrium
with fibrinoid pattern and presented in the central
lumen of blood vessels. The tumor cells invaded the
myometrium to a depth of 0.6 cm. Mitotic figure
counts were four per 10 high-power fields. There was
no villous formation. Most neoplastic cells stained with
human placental lactogen (hPL) (Figure 3), whereas
few stained with hCG (Figure 4). These histopathologic
findings suggested the diagnosis of PSTT. After sur-
gery, two cycles of EMA were administered, repeated
at 8-day intervals. The patient’s serum hCG dropped
progressively to zero on August 7, 2003 (Figure 5). She
was alive and well at the time of writing.
Figure 2. Photomicrograph of placental site trophoblastic
tumor demonstrating a mononuclear cell population and
occasional giant cells (hematoxylin & eosin, original magni-
fication 20 × 10).
Discussion
PSTT was originally described by Kurman et al in a se-
ries of 12 patients, none of whom succumbed to their
disease or had evidence of metastasis [1]. The term
trophoblastic pseudotumor was used to reflect the
clinically benign nature of this tumor. In 1981, Twiggs
et al reported the death of a patient with trophoblastic
pseudotumor due to distant metastasis [2]. Scully
and Young then renamed the tumor placental site
trophoblastic tumor to represent its malignant poten-
tial [3].
PSTT is a neoplasm composed of a monomorphic
population of intermediate trophoblastic cells. His-
tologically, it is characterized by a mononuclear cell
population that infiltrates the myometrium and its
blood vessel walls. There is no dimorphic pattern of
cytotrophoblasts and syncytiotrophoblasts. Villous
formation is not present, while multinuclear giant cells
are occasionally identified [4]. Generally, hemorrhage
and necrosis, which are usually associated with cho-
riocarcinoma, are not found. Immunohistochemical
Figure 1. Gross specimen of the uterus. The tumor is located at
the cervix.
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staining is diffusely positive for serum hPL and only
focally positive for hCG. hPL has been used as a tumor
marker for gestational trophoblastic disease. Patients
with PSTT may express low levels of hCG but have
increased levels of hPL. However, we cannot measure
serum hPL in our institution, so β-hCG was the only
available tumor marker for this patient. The variable
and often low level of hCG detected in this tumor
reflects the lack of syncytiotrophoblasts.
Our patient met the diagnostic criteria for PSTT on
the histopathologic findings from the resected uterus.
The initial pathologic diagnosis was choriocarcinoma.
According to a Japanese study, a correct diagnosis of
PSTT is achieved in only 35% of cases on the basis of
curettage specimens [5]. Vardar and Altintas showed
that 50% to 100% of intermediate trophoblastic cells
stain positive for hPL but less than 10% of tumor cells
stain positive for hCG in patients with PSTT [6]. PSTT
must be differentiated from choriocarcinoma and an
exaggerated placental site. Compared with choriocar-
cinoma, PSTT has characteristic microscopic findings
such as a monomorphic cell population, a pattern of
immunohistochemical staining for hPL and occasionally
Figure 3. Human placental lactogen (hPL)-positive intermediate
trophoblastic cells (hPL stain, original magnification 40 × 10).
Figure 4. Human chorionic gonadotropin (hCG)-positive inter-
mediate trophoblastic cells (hCG stain, original magnifica-
tion 40 × 10).
hCG, and, usually, lack of necrosis and hemorrhage.
PSTT can also be distinguished from an exaggerated
placental site by lack of villous formation and occasional
mitotic figures [7].
PSTT may complicate or follow any type of normal
or abnormal pregnancy and affects women of all re-
Figure 5. Serum human chorionic gonadotropin (hCG)
level during therapy and follow-up. EMA = etoposide +
methotrexate + actinomycin-D; CO = cyclophosphamide +
vincristine; PE = cisplatin + etoposide; OP = operation.
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productive ages. The most frequent gestational event
reported is antecedent term delivery followed by
spontaneous and therapeutic abortions [8]. Symp-
toms may develop from several weeks to up to 15 years
after the preceding pregnancy [6]. Vaginal bleeding or
amenorrhea is the usual mode of presentation. The an-
tecedent pregnancy of our patient ended in therapeu-
tic abortion. Nine months after the abortion, vaginal
bleeding occurred. Ultrasonography usually shows an
echogenic mass that may involve the endometrium and
myometrium. The lesion was tiny after chemotherapy in
this patient, so sonography failed to show the tumor.
Most PSTTs behave in a benign fashion, but ap-
proximately 10% to 15% are clinically malignant [9].
The tumors are usually non-metastatic and remain
confined to the uterus. However, they can spread to the
peritoneum, liver, pancreas, lungs, and brain late in
their course and are usually not treatable in this setting
as they do not respond to chemotherapy. Tumors with
more than five mitoses per 10 high-power fields have
an increased propensity for metastatic disease [8].
However, there have been several reports of recurrence
developing with tumors with less than two mitotic
figures per 10 high-power fields [10,11]. An interval of
more than 2 years since the preceding pregnancy is
an independent adverse prognostic factor [12]. Surgery
remains the cornerstone of therapy, and primary
total abdominal hysterectomy is the optimal therapy
once the diagnosis of PSTT is established [12,13].
EMA/CO, an effective chemotherapeutic regimen,
is the first-line treatment of choice for high-risk ges-
tational trophoblastic tumors. Swisher and Drescher
demonstrated that the total response rate to EMA/CO
among metastatic PSTT was 71%, with a complete
response rate of 28% [14]. Our present case initially
responded to EMA/CO therapy but later became un-
responsive. Chemotherapy-resistant persistent gesta-
tional trophoblastic disease may suggest PSTT [15].
A suggestion of PSTT may also arise from relatively
low serum β-hCG concentrations [16]. For our pa-
tient, the diagnosis of PSTT was proved only by histo-
pathologic findings from the surgical specimen.
Hopkins et al suggest that the trophoblastic cells
producing hCG are responsive to chemotherapeutic
agents and that non-hCG producing trophoblasts
are resistant [17]. It has been reported that failure
of EMA/CO indicates that the tumor is aggressive
[18]. Recently, Newlands et al used EMA/EP as the
primary treatment for eight patients with metastatic
PSTT, obtaining a 50% complete remission rate [19].
The clinical impression is that cisplatin should be
included in the initial treatment of PSTT. We used
one cycle of chemotherapy consisting of EP with some
benefits before surgery. Adjuvant chemotherapy
with two cycles of EMA was given, although the
role of EMA has not yet been established.
To our knowledge, this is the first report of PSTT
in the endocervical canal. The clinical behavior of
endocervical PSTT is still unclear and there are no
reliable prognostic indicators. It is also difficult to
predict the clinical behavior of PSTT from serum hCG
concentrations and the mitotic count in tumor cells.
However, in general, this disease is highly curable
if recognized and treated appropriately. Immediate
hysterectomy is required for patients without meta-
stasis until reliable prognostic indicators for PSTT
are clearly understood.
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